Heart failure is an important cause of morbidity and mortality in many industrial countries, and dilated cardiomyopathy (DCM) is one of its major causes. Molecular genetic studies over the past 2 decades have revealed many mutations of various genes in DCM patients, but the precise mechanisms of how such mutations lead to DCM remain largely unknown partly because of a lack of good animal models of DCM. The authors established the mouse model of DCM by expressing a mutated cardiac ␣-actin gene, which has been reported in patients with DCM, in the heart. The transgenic mice showed gradual dilatation and dysfunction of the left ventricle, resulting in death by heart failure. These phenotypes of the transgenic mice were quite similar to those of human DCM. The number of apoptotic cardiomyocytes and protein levels of p53 were increased in the hearts of the DCM mice. Overexpression of Bcl-2, an antiapoptotic factor, or downregulation of p53 decreased the number of apoptotic cardiomyocytes and improved cardiac function. The DCM mice showed activation of CaMKII␦. The inhibition of CaMKII␦ prevented the increase in p53 and apoptotic cardiomyocytes and ameliorated cardiac function. These results suggest that CaMKII␦ plays a critical role in the development of heart failure in part by accumulation of p53 and induction of cardiomyocyte apoptosis in the DCM mouse model. The inhibition of CaMKII␦ may become a new therapeutic strategy for DCM patients.
Role of RBM25/LUC7L3 in Abnormal Cardiac Sodium Channel Splicing Regulation in Human Heart Failure
Summary: The authors have previously shown that human heart failure is associated with abnormal mRNA splicing of the cardiac sodium channel. This abnormal mRNA splicing results in truncated sodium channels that are nonfunctional and a reduction in sodium channel current to levels known to cause sudden death. The authors explored the mechanisms by which this abnormal splicing occurs. Using microarray comparisons of diseased and normal human hearts, they identified 2 splicing factors, RBM25 and LUC7L3, that were necessary and sufficient to cause the abnormal sodium channel splicing. These factors were upregulated by hypoxia and elevated angiotensin II, conditions known to be present in heart failure. Moreover, the authors showed that the responses of white cells and heart to these 2 inciting stimuli were equivalent. The potential clinical implications of these findings include a possible mechanism whereby hypoxia is arrhythmogenic and blockade of the renin-angiotensin system is antiarrhythmic. Moreover, if white cell sodium channel splicing in vivo correlates with that in the myocardium, it may be possible to develop a blood test to assess sodium channel availability and arrhythmic proclivity. Finally, this work defines potential therapeutic targets to address arrhythmic risk in human heart failure.
Conclusions: Of the 17 mRNA splicing factors upregulated in heart failure, RBM25 and LUC7L3 were sufficient to explain the increase in truncated forms and the reduction in full-length Na ϩ channel transcript. Because the reduction in channels was in the range known to be associated with sudden death, interruption of this abnormal mRNA processing may reduce arrhythmic risk in heart failure. 2 
Protein Aggregates and Novel Presenilin Gene Variants in Idiopathic Dilated Cardiomyopathy
Summary: Heart failure is a progressive and ultimately fatal disease, which represents a leading public health problem worldwide. Despite substantial advances in the clinical management of heart failure, the only current permanent therapeutic option is heart transplantation. However, the limited supply of functional organs for transplantation and the age threshold for the surgical intervention constrain the scope of this treatment modality. The majority of cases of heart failure are ischemic in origin. The second most frequent origin of nonischemic heart failure is "idiopathic" dilated cardiomyopathy, in which no other causative events can be recognized. Recent studies highlight the recognition of the public health importance of a large number of diseases associated with defects in the ability of proteins to fold, leading to the accumulation of cytotoxic protein deposits. This group of diseases includes amyloidosis and various neurodegenerative disorders such as Alzheimer disease. Preliminary evidence suggests that idiopathic dilated cardiomyopathy may be included among these misfolding diseases. In addition, mutations in the same genes causing Alzheimer disease in a significant percentage of cases can also be at the origin of idiopathic dilated cardiomyopathy. Interestingly, a dual mechanism seems to mediate the effect of these genetic variations: (1) changes in the control of Ca 2ϩ -handling proteins causing defect in the contractile function, and (2) cell damages associated with the protein aggregation process. The incidence, prognosis, and therapeutic options for idiopathic dilated cardiomyopathy may therefore be greatly advanced by establishing a fundamental understanding of key factors leading to the disease.
Conclusions: On the basis of these findings, the authors propose that 2 mechanisms may link protein aggregation and cardiac function: oligomer-induced changes on Ca 2ϩ handling and a direct effect of PSEN1 sequence variants on excitation-contraction coupling protein function. 3 
Transcriptomic Biomarkers for the Accurate Diagnosis of Myocarditis
Summary: New diagnostic tools based on gene signatures derived from the entire complement of messenger RNAs in a cell or tissue have become established in the clinical management of certain disorders, particularly cancer. The comprehensiveness of this approach contributes to its accuracy. Myocarditis is a disorder that causes a substantial proportion of patients presenting with new-onset heart failure and left ventricular dysfunction. Typically diagnosed by endomyocardial biopsy and evaluated with histological criteria called the Dallas criteria, clinical management is hampered by low sensitivity and specificity and the need for multiple cardiac biopsies. The present study suggests that the application of a transcriptomicbased biomarker can substantially improve the diagnostic accuracy of heart biopsy for myocarditis. Using endomyocardial biopsy tissue obtained at the time of clinical presentation, the authors developed a molecular signature comprising 62 genes that predicted with high accuracy the presence of myocarditis in a population of 48 patients. Importantly, this required evaluation of tissue from a single endomyocardial biopsy sample and therefore is clinically practical. The present results could provide treating physicians with important and accurate diagnostic information about individual patients and could provide tools for personalized treatment or monitoring. Given emerging treatment strategies for viral and inflammatory myocarditis, accurate diagnostic tools are of increased importance.
Conclusions: Together, these findings demonstrate that transcriptomic biomarkers from a single endomyocardial biopsy can improve the clinical detection of patients with inflammatory diseases of the heart. This approach advances the clinical management and treatment of cardiac disorders with highly variable outcome. 4
Peripartum Cardiomyopathy as a Part of Familial Dilated Cardiomyopathy
Summary: Anecdotal cases with familial clustering of peripartum cardiomyopathy (PPCM) or joint occurrence of PPCM and idiopathic dilated cardiomyopathy (DCM) within families have been reported. The authors performed the first systematic study of the relation between PPCM and familial DCM. In a substantial number of DCM families (5/90), cases of PPCM were found, and, more important, previously undiagnosed cases of DCM were identified in all 3 families of PPCM patients who did not show a full recovery. Moreover, the authors' results support the genetic nature of the disease in 1 DCM family with PPCM: The authors identified a mutation in the gene encoding cardiac troponin C (TNNC1). They therefore conclude that PPCM can be a manifestation of familial DCM. Obviously, further research is needed to confirm these observations in a larger series of patients. However, these findings already have several clinical implications and may change clinical practice and thinking about PPCM. Because PPCM can be the first manifestation of familial DCM, the authors recommend presymptomatic cardiological screening for covert DCM in first-degree family members of PPCM patients without recovery of left ventricular function and dimensions. Second, cardiological screening during pregnancy should be considered for healthy women (ie, without proven previous signs of DCM) who are first-degree family members of familial DCM patients, and this should be extended into the puerperium.
Conclusions:
The findings strongly suggest that a subset of PPCM is an initial manifestation of familial DCM. This may have important implications for cardiological screening in such families. 5
Distinct Epigenomic Features in End-Stage Failing Human Hearts
Summary: Molecular research in heart failure points to the hypothesis that a generic cardiac genomic response is activated in the failing myocardium regardless of the original inciting cause. This cardiac genomic stress response is typified by the reexpression of fetal genes, upregulation of fibrosis-related genes, and others. It may also reflect unifying features of a failed myocardium such as fibrosis, altered energy use, vascular rarefaction, cell death, and altered contractility, all of which are features found in the failing myocardium, again regardless of the inciting cause. The epigenome refers to "marks" on the genome, including DNA methylation and histone modification. The epigenome regulates the expression of underlying genes, and recent evidence suggests that part of the epigenome may be altered by diet and the environment. In their research, the authors have examined the genome-wide landscape of the epigenome of healthy and end-stage cardiomyopathic human hearts. They have determined that distinct epigenomic patterns exist in important DNA elements of the human cardiac genome in the failing myocardium. Individually, sites of differential epigenomic patterns may control the expression of specific genes with critical functions in the progression of heart failure. However, whether the altered epigenome is simply a consequence in end-stage disease or actually contributes to disease progression remains to be determined. This work now opens an important new avenue of research because the epigenome may represent a drug discovery target for novel heart failure therapy.
Conclusions: Distinct epigenomic patterns exist in important DNA elements of the cardiac genome in human end-stage cardiomyopathy. The epigenome may control the expression of local or distal genes with critical functions in myocardial stress response. If epigenomic patterns track with disease progression, assays for the epigenome may be useful for assessing prognosis in heart failure. Further studies are needed to determine whether and how the epigenome contributes to the development of cardiomyopathy. 6
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca 2؉ -ATPase in Patients With Advanced Heart Failure
Summary: The Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) phase 2, randomized, double-blind trial evaluated adeno-associated virus type 1 (AAV1)/sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA2a) versus placebo in 39 patients. A deficiency in SERCA2a has been identified in cardiomyocytes from failing human hearts. AAV1/SERCA2a is a viral vector delivering the deficient SERCA2a gene by intracoronary infusion into patients with advanced heart failure. AAV1/SERCA2a in this study population demonstrated no untoward safety findings; there appeared to be fewer cardiovascular adverse events in the high-dose group compared with placebo. The study met the prospectively defined efficacy end points comprising 7 different parameters in 5 clinically relevant domains. All 3 predefined analyses were met at the individual-level, group-level (in functional and left ventricular function/remodeling domains), and clinical outcomes (duration of cardiovascular hospitalizations). High-dose AAV1/SERCA2a compared with placebo also demonstrated significantly delayed and reduced frequency of adverse cardiovascular events per patient, reaching statistical significance at 12 months (Pϭ0.003). The positive signals across 5 domains support the contention that high-dose AAV1/SERCA2a induced meaningful biological activity. Results from this small study indicate a decrease in symptoms of heart failure, augmented functional status, a decrease in natriuretic peptide levels, beneficial ventricular reverse remodeling, and a significant increase in time to and decreased frequency of adjudicated cardiovascular events in the high-dose group versus placebo. The totality of the data, limited by the small study size, strongly supports moving forward with confirmatory clinical studies of AAV1/SERCA2a for patients with severe heart failure. This CUPID trial represents a new approach to the treatment of heart failure with enzyme replacement via gene therapy.
Conclusions:
The CUPID study demonstrated safety and suggested benefit of adeno-associated virus type 1/sarcoplasmic reticulum Ca 2ϩ -ATPase in advanced heart failure, supporting larger confirmatory trials. 7
Cardiac Raptor Ablation Impairs Adaptive Hypertrophy, Alters Metabolic Gene Expression, and Causes Heart Failure in Mice
Summary: Mammalian target of rapamycin (mTOR) is an evolutionary conserved kinase that regulates cell growth. Rapamycin is clinically used as an immunosuppressant and as potent antiproliferative agents; several rapalogs are in trials for cancer therapy. Rapamycin inhibits, at least in part, the activities of mTOR in mTOR complex (mTORC) 1, 1 of the 2 distinct multiprotein complexes in which mTOR is found. The recently developed active-site mTOR inhibitors inhibit mTORC1 and mTORC2. In the present study, the authors established that mTORC1 is essential for normal cardiac function and that its activity becomes even more important with increased cardiac work. Thus, deletion of raptor, an essential component of mTORC1, from cardiomyocytes in adult mice caused dilated cardiomyopathy within 6 weeks. Moreover, increased load by dynamic exercise or aortic constriction accelerated progression into heart failure without a prior phase of adaptive hypertrophy. This strengthens the perception that appropriate growth responses with intact signaling via the insulin/insulin-like growth factor/Akt/mTOR pathway are important when the heart must generate more work, which applies to various clinical conditions such as hypertension, postinfarct remodeling, and valve disease. Notably, this signaling pathway is affected during anticancer therapy and therefore may be involved in the development of cardiomyopathy in these patients. Besides slowing of protein synthesis, we show that cardiac mTORC1 inactivation affects mitochondria, substrate oxidation, autophagy, and apoptosis. These mechanistic insights may lead to the development of novel approaches to prevent cardiac dysfunction. Our study also underlines that monitoring of cardiac performance in clinical trials with active-site mTOR inhibitors is important.
Conclusions:
The study results demonstrate an essential function for mTORC1 in the heart under physiological and pathological conditions and are relevant for the understanding of disease states in which the insulin/insulin-like growth factor signaling axis is affected, such as diabetes mellitus and heart failure or after cancer therapy. 8
Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure
Summary: Chronic and acute stress to the heart results in a pathological remodeling response accompanied by cardiomyocyte hypertrophy, fibrosis, pump failure, myocyte degeneration, and apoptosis, which often culminate in heart failure and sudden death. Although classic pharmacological treatment strategies can reduce remodeling and prolong survival in heart failure patients, these therapies are ultimately ineffective in preventing progression of the disease. Previously, the authors identified a microRNA, miR-208, encoded within an intron of the Myh6 gene that regulates the cardiac stress response. Although genetic deletion of miR-208 in mice failed to induce an overt phenotype at baseline, in response to several forms of cardiac stress, miR-208 -null mice showed virtually no cardiomyocyte hypertrophy or fibrosis and were unable to upregulate Myh7 expression. Data presented in this study show that delivery of a locked nucleic acid-modified anti-miR against miR-208a in mice induces highly specific and sustained silencing of miR-208a in the heart without any observable side effects. Therapeutic silencing of miR-208a via subcutaneous delivery of anti-miR-208a prevents pathological cardiac remodeling, functional deterioration, and lethality during heart disease. These beneficial effects correspond to significant changes in miRNAs within plasma. These data show the potent beneficial effects of miR-208a inhibition, which could be very relevant for patients suffering from heart failure. Because miR-208a is the sole cardiac-specific miRNA annotated so far, the authors believe that anti-miR-208a might become a combination therapy with the current standard of care.
Conclusions:
These studies indicate the potential of oligonucleotidebased therapies for modulating cardiac miRNAs and validate miR-208 as a potent therapeutic target for the modulation of cardiac function and remodeling during heart disease progression. 9
H11 Kinase/Heat Shock Protein 22 Deletion Impairs Both Nuclear and Mitochondrial Functions of STAT3 and Accelerates the Transition Into Heart Failure on Cardiac Overload
Summary: Cardiac overload represents a major cause of heart failure and triggers the activation of multiple stress-activated pathways, including the expression of the heat shock protein H11 kinase/Hsp22 (Hsp22). The objective of the present study was to determine the specific function of Hsp22 in a context of overload. This goal was achieved by generating a knockout mouse model of Hsp22 deletion. The authors show that under pressure overload generated by aortic constriction, deletion of Hsp22 accelerates the transition into heart failure and increases mortality. Specifically, Hsp22 represents a necessary and previously undescribed activator of the stressregulated transcription factor STAT3. The authors also illustrate that Hsp22 couples the activity of STAT3 as a transcription factor, together with its novel function as an activator of mitochondrial respiration. Therefore, Hsp22 represents a novel mode of cardiac stress response by combining the adaptation of gene expression and that of mitochondrial respiration.
Conclusions: This study found that Hsp22 represents a previously undescribed activator of both nuclear and mitochondrial functions of STAT3, and its deletion in the context of pressure overload in vivo accelerates the transition into heart failure and increases mortality. 10
Puma Deletion Delays Cardiac Dysfunction in Murine Heart Failure Models Through Attenuation of Apoptosis
Summary: p53 is a tumor suppressor gene that exerts its effect through transcriptional activation. Puma (p53-upregulated modulator of apoptosis) and Mdm4 represent 2 critical p53 targets; although Puma serves as the major downstream proapoptotic effector of p53, Mdm4 inhibits p53-mediated apoptosis by direct binding. Puma is a unique member of the Bcl-2 family because it integrates and implements most signals mediated by different apoptosis inducers. In the present study, the authors used Puma knockout mice in 2 heart failure models, triggered by pressure overload and heart-specific Mdm4-ablation, and found that Puma-induced apoptosis may play a role in the progression of heart failure. Interestingly, Puma can be activated not only by pressure overload but also by myocardial ischemia. The results thus provide insight into the function of the Mdm4-p53-Puma axis in cardiomyocytes, which could ultimately aid in the development of antiapoptotic drug candidates to treat various cardiac diseases. Moreover, lack of Puma does not recapitulate the tumor-prone phenotype observed in p53-negative mice. Because the Mdm4-p53-Puma interface has also been the focus of recent drug discovery efforts in cancer, additional functional analysis of this system in the heart could contribute to the development of safer anticancer therapies with minimal cardiotoxic side effects. Of note, Puma is not the only contributor to cardiac signaling during heart failure, and further studies are required to elucidate its connection with other apoptotic pathways. In conclusion, Puma antagonists might be developed in the future to provide cardiac protection without increasing susceptibility to tumors, an adverse effect of therapies based on p53 inactivation.
Conclusions:
The data indicate that Puma might be a critical component of the apoptotic signaling pathways that contribute to ventricular remodeling and heart failure. Therefore, Puma inactivation may serve as a preferential target to prevent heart failure induced by cellular stress. 11
Absence of SOCS3 in the Cardiomyocyte Increases Mortality in a gp130-Dependent Manner Accompanied by Contractile Dysfunction and Ventricular Arrhythmias
Summary: The serum level of interleukin-6, a ligand for gp130 receptor, is elevated in patients with congestive heart failure (CHF). These elevated levels correspond to worsening functional class, increased hospitalization rates, and poor survival. This suggests that chronic activation of cardiac gp130 signaling may be detrimental to cardiac function. The interleukin-6 family of cytokines is known to induce the expression of SOCS3 through gp130 signaling activation. The expressed SOCS3 binds to gp130 and inhibits the receptor's downstream signaling. Accordingly, SOCS3 tightly regulates the duration and intensity of gp130 signaling in a classic negativefeedback manner. It has recently been reported that there is a significant decrease in SOCS3 protein or mRNA in human failing hearts. This also implies that chronic gp130 activation and alterations in SOCS3 levels may be involved in the pathogenesis of congestive heart failure. In this study, the authors sought to determine the role of SOCS3 regulation on gp130 signaling in the heart using cardiacspecific SOCS3 knockout mice. They demonstrated that the absence of SOCS3 allows for unregulated, chronic activation of gp130 signaling, leading to contractile dysfunction and ventricular arrhythmias accompanied by abnormal myofilament Ca 2ϩ sensitivity and SR Ca 2ϩ overload. These results demonstrated the importance of homeostatic regulation of cardiac gp130 signaling via SOCS3 and are the first to support the possibility that abnormalities in SOCS3 regulation on cardiac gp130 signaling could be a novel disease mechanism underlying congestive heart failure and fatal arrhythmias in humans as well.
Conclusions:
The results demonstrate an important role of SOCS3 regulation on cardiac gp130 signaling in the pathogenesis of contractile dysfunction and ventricular arrhythmias. 12
Conditional Transgenic Expression of Fibroblast Growth Factor 9 in the Adult Mouse Heart Reduces Heart Failure Mortality After Myocardial Infarction
Summary: Paracrine mechanisms are thought to contribute to the beneficial effects of bone marrow cells on perfusion and function of the infarcted heart that have been demonstrated in experimental studies and some clinical trials. The authors have previously identified fibroblast growth factor 9 (FGF9) as 1 of Ͼ100 paracrine factors that are secreted from bone marrow cells after myocardial infarction. In the embryonic heart, FGF9 is expressed by the epicardium and endocardium and provides an epithelial-to-mesenchymal signal to stimulate coronary artery formation and cardiomyoblast expansion in the developing myocardium. FGF9, however, is expressed only at very low levels in the adult heart. Using a tetracycline-responsive binary transgene system based on the ␣-myosin heavy chain promoter, the authors show that conditional expression of FGF9 in the adult mouse myocardium supports functional adaptation and survival after myocardial infarction. Transgenic FGF9 stimulated left ven-tricular hypertrophy with microvessel expansion, reduced interstitial fibrosis, attenuated fetal gene expression, preserved diastolic but improved systolic function, and markedly reduced heart failure mortality. A single injection of an adenoviral vector encoding FGF9 promoted similar improvements in left ventricular systolic function and survival after myocardial infarction. Mechanistically, FGF9 acted primarily on endothelial cells to promote angiogenesis and paracrine release of prohypertrophic factors, including bone morphogenetic protein 6. These observations support the idea that secretome analyses in bone marrow cells can lead to the identification of secreted factors with therapeutic activity after myocardial infarction. Specifically, the data suggest a previously unrecognized therapeutic potential for FGF9 after myocardial infarction.
Conclusions: Conditional expression of FGF9 promotes myocardial vascularization and hypertrophy with enhanced systolic function and reduced heart failure mortality after myocardial infarction. These observations suggest a previously unrecognized therapeutic potential for FGF9 after myocardial infarction. 13
Human Cardiac Stem Cell Differentiation Is Regulated by a Mircrine Mechanism
Summary: Effective repair of the damaged heart requires the recovery of the normal architecture and function of the organ. Myocardial regeneration mediated by activation and differentiation of human cardiac stem cells commonly results in the formation of small myocytes with fetal-neonatal characteristics. The number of new cells exceeds the number of myocytes lost, but the replacement of cardiac mass is incomplete because the regenerated myocytes fail to acquire the adult phenotype. This limitation in myocyte maturation has been partly overcome by enhancing the expression of microRNA-499 in human cardiac stem cells; microRNA-499 represses genes responsible for the primitive state of these cells, promoting the program of myocyte differentiation, structurally and functionally. In the presence of microRNA-499, the regenerated parenchymal cells increase in size and acquire electric and mechanical properties of adult cells. This process occurs by the physiological translocation of microRNA-499 from myocytes to human cardiac stem cells via gap junction channels. Importantly, the potentiated reconstitution of the infarcted myocardium has significant effects on the anatomic remodeling and hemodynamic performance of the injured heart. Understanding the molecular control that regulates the differentiation of human cardiac stem cells into functionally competent cardiomyocytes may be critical for the implementation of stem cell therapy in the diseased heart.
Conclusions:
The recognition that miR-499 promotes the differentiation of human cardiac stem cells into mechanically integrated cardiomyocytes has important clinical implications for the treatment of human heart failure. 14
Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction
Summary: Mineralocorticoid receptor (MR) antagonism beneficially modulates heart failure progression and survival after myocardial infarction, but the contribution of renal, vascular, or cardiac MR blockade remained obscure. The present study highlights the importance of the cardiomyocyte MR for left ventricular remodeling and failure after myocardial infarction. Cardiomyocyte-specific inactivation of the MR gene improved infarct healing and prevented progressive adverse cardiac remodeling and contractile dysfunction, with the likely contribution of both early and late effects. In the early phase after myocardial infarction, cardiomyocyte-specific MR deletion reduced cardiomyocyte apoptosis, enhanced infarct neovessel formation, and attenuated infarct expansion, whereas in the late post-myocardial infarction phase, cardiomyocyte hypertrophy, reactive fibrosis, and oxidative stress in the surviving left ventricular myocardium were prevented. These results suggest that the clinical benefits of MR blockade in patients with acute or chronic ischemic heart failure are mediated largely via a cardiomyocyte-dependent mechanism. Furthermore, these results provide strong evidence that more favorable effects on cardiac healing and remodeling after myocardial infarction can be achieved by immediate initiation of MR blockade.
Conclusions: Cardiomyocyte-specific MR deficiency improved infarct healing and prevented progressive adverse cardiac remodeling, contractile dysfunction, and molecular alterations in ischemic heart failure, highlighting the importance of cardiomyocyte MR for heart failure development and progression. 15
Omega-3 Fatty Acids Prevent Pressure Overload-Induced Cardiac Fibrosis Through Activation of Cyclic GMP/Protein Kinase G Signaling in Cardiac Fibroblasts
Summary: Heart failure is the leading reason for hospital admissions and is the most expensive Medicare expenditure. About half of heart failure cases are due to diastolic dysfunction. One of the main causes of diastolic dysfunction is cardiac fibrosis, and no therapies are available to prevent or treat cardiac fibrosis. Transforming growth factor-␤1-induced cardiac fibroblast transformation and proliferation are the key events leading to cardiac fibrosis. This study shows that -3 polyunsaturated fatty acids prevent pressure overloadinduced cardiac fibrosis and subsequent cardiac dysfunction. This study also demonstrates that in cardiac fibroblasts, eicosapentaenoic acid and docosahexaenoic acid increase cyclic GMP levels by increasing phosphorylated endothelial nitric oxide synthase and endothelial nitric oxide synthase protein levels and nitric oxide production, and they exert their antifibrotic effect through activation of the cyclic GMP/protein kinase G pathway and subsequent blocking of transforming growth factor-␤1-induced nuclear translocation of phospho-Smad2 and phospho-Smad3. This study defines the beneficial effects of -3 polyunsaturated fatty acids on cardiac fibrosis and cardiac dysfunction and clarifies the underlying mechanisms. In addition, this study provides the basis for extending the application of -3 polyunsaturated fatty acids, which appear to be exceptionally safe and well tolerated, to the prevention of cardiac fibrosis.
Conclusions: Omega-3 fatty acids prevent cardiac fibrosis and cardiac dysfunction by blocking transforming growth factor-␤1-induced phospho-Smad2/3 nuclear translocation through activation of the cyclic GMP/protein kinase G pathway in cardiac fibroblasts. 16 
Long-Term Cardiac Pro-B-Type Natriuretic Peptide Gene Delivery Prevents the Development of Hypertensive Heart Disease in Spontaneously Hypertensive Rats
Summary: Today, the clinical use of B-type natriuretic peptide (BNP) is limited to the treatment of acute heart failure. Concerns have been raised about the use of this hormone in humans because of the risk of worsening renal function in patients with reduced cardiac output and low blood pressure. However, the recent results from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) have shown that BNP is safe in patients with acute heart failure, although the benefit of short-term BNP administration in these patients remains questionable. The current study has demonstrated the possible beneficial effects of long-term BNP administration in hypertension to prevent the development of hypertensive heart disease and the worsening of cardiac remodeling. Indeed, the use of a low yet prolonged dose of BNP with more stable hemodynamic conditions where blood pressure is high may be a more efficacious therapeutic option. In addition, long-term BNP delivery has also been challenging because of its short in vivo half-life and proteic structure, which limits its use as an intravenous or subcutaneously administered drug. In this regard, however, novel technologies are arising that allow oral delivery of proteins, making the long-term use of this cardiovascular hormone feasible. It is conceivable that the sustained use of oral BNP, in the presence of stable hemodynamic conditions, may prevent the progression of hypertensive heart disease and cardiac dysfunction if used early in the course of hypertension. Alternatively, novel gene delivery strategies for BNP overexpression could represent a high-risk high-impact therapeutic strategy, especially in the setting of resistant hypertension and hypertrophic cardiomyopathy, to protect the heart.
Conclusions: AAV9 vector facilitates sustained cardiac proBNP overexpression and improves left ventricular function in hypertensive heart disease. Long-term proBNP delivery improved both systolic and diastolic function. The effects on cardiac structure and function occurred independent of blood pressure-lowering effects in normal Wistar rats. 17
Calcineurin Splicing Variant Calcineurin A␤1 Improves Cardiac Function After Myocardial Infarction Without Inducing Hypertrophy
Summary: Because the adult mammalian heart has limited regenerative capacity, the considerable loss of cardiomyocytes after myocardial infarction leads to the formation of a permanent scar and the onset of numerous pathological events that culminate in heart failure. Modulating this response may lessen the consequences of myocardial infarction and offers opportunity for therapeutic intervention. In this work, the authors explored the potential benefit of cardiac overexpression of calcineurin A␤1 (CnA␤1), an alternative splicing isoform of the phosphatase calcineurin found in both progenitor cells and regenerative tissues. Although other calcineurin isoforms play a detrimental role in heart disease, a unique domain in the carboxyterminus of the protein confers CnA␤1 the ability to activate a protective pathway in the cardiomyocyte. Mice overexpressing CnA␤1 show significantly improved cardiac function and reduced scar formation after infarction. The authors identified the underlying molecular mechanism to be interaction between CnA␤1 and mTOR complex 2 and subsequent activation of the Akt pathway and amino acid biosynthesis response. This work suggests that alternative splicing isoforms of the same protein can have opposite effects on heart pathophysiology and highlights manipulation of alternative splicing in general, and induction of CnA␤1 in particular, as a future therapeutic approach.
Conclusions: Calcineurin A␤1 shows a unique mode of action that improves cardiac function after myocardial infarction, activating different cardioprotective pathways without inducing maladaptive hypertrophy. These features make CnA␤1 an attractive candidate for the development of future therapeutic approaches. 18
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
Summary: Heart failure represents an enormous medical and societal burden. In the past, hypertension and valvular heart disease were the primary causes of heart failure in the United States. In recent years, however, coronary artery disease has emerged as the major cause of heart failure (ischemic cardiomyopathy). Notably, the degree of left ventricular dysfunction in ischemic cardiomyopathy is often out of proportion to the amount of overtly infarcted heart tissue. This suggests that ischemia per se can cause cardiac dysfunction. The Prolyl Hydroxylase Domain-Containing Protein (PHD) prolyl hydroxylases translate changes in oxygen bioavailability into changes in the abundance of the hypoxia-inducible factor transcriptional factor, a master regulator of cellular response to hypoxia. Under low oxygen conditions, such as occurs during ischemia, PHD function is impaired and hypoxia-inducible factor becomes active. The authors show that genetically ablating PHD activity in the hearts of mice causes ultrastructural, histological, and functional changes reminiscent of ischemic cardiomyopathy. They show that long-term expression of a constitutively active hypoxia-inducible factor variant also leads to cardiomyopathy. Additionally, they document hypoxiainducible factor upregulation in a murine chronic myocardial ischemia model and in autopsy samples from patients with ischemic cardiomyopathy. Collectively, these data suggest that long-term PHD inactivation and subsequent long-term hypoxia-inducible factor activation contribute to the pathogenesis of ischemic cardiomyopathy.
Conclusions: Sustained loss of PHD activity and subsequent hypoxiainducible factor activation, as would occur in the setting of chronic ischemia, are sufficient to account for many of the changes in the hearts of individuals with chronic coronary artery disease. 19 
Reduced Degradation of the Chemokine MCP-3 by Matrix Metalloproteinase-2 Exacerbates Myocardial Inflammation in Experimental Viral Cardiomyopathy
Summary: Cardiac inflammation is one important pathomechanism in the progression of heart failure. Although in some cardiac diseases inflammation might be helpful (eg, after acute myocardial infarction), uncontrolled inflammation is detrimental in most forms of cardiomyopathy. Insights into the pathophysiological control of inflammation are needed to develop new interventions. Matrix metalloproteinases (MMPs) are deregulated in acute and chronic heart failure. In most studies, the gelatinases MMP-2 and MMP-9 are especially upregulated. Although MMPs were thought to process matrix proteins only and therefore trigger remodeling, there is recent evidence that some MMPs process cytokines as well as chemokines, thereby modulating the inflammatory process. This study enhances our knowledge about the immunmodulatory properties of MMPs, especially relative to inflammatory cardiomyopathies. MMP-2 degrades the chemokine MCP-3. The authors show here that this is one beneficial mechanism that controls inflammation during viral myocarditis. Loss of this degradation by MMP-2 knockout increases protein levels of the chemokine MCP-3, which fuels the inflammatory process leading to increased transendothelial migration of inflammatory cells into the cardiac tissue. This experimental overreaction of the immune system could be prevented by neutralizing MCP-3 in vivo. This shows that a complete inhibition of MMP-2 (and similar data exists for MMP-9) is detrimental in experimental viral heart disease. Preservation of MMP-2 should be one goal in treating heart failure with an increased inflammatory process because an uncontrolled inflammatory reaction leads to cardiac failure. This might be a double-edged sword, given that future drug therapies target the MMP system to prevent adverse remodeling.
Conclusions: Loss of MMP-2 increased the inflammatory response after CVB3 infection, which impaired cardiac function and survival during CVB3-induced myocarditis. MMMP-2-mediated chemokine cleavage has an important role in cardiac inflammation as a negative feedback mechanism. 20
An ␣ 2C -Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the ␤-Blocker Bucindolol in Chronic Heart Failure
Summary: Drugs that have been shown to be effective in a disease population work in only a subset, typically estimated at 30 -50% of the total. It has long been a dream of those involved in drug development to be able to more accurately define a drug's responsive subpopulation, ideally by a widely available and accurate biomarker. The ␣ 2C -adrenergic receptor regulates norepinephrine (NE) release from adrenergic nerve terminals, including those in the heart. Bucindolol is a novel ␤-adrenergic receptor-blocking agent that reduces NE release, the only ␤-blocking agent that does so. This reduction in NE by bucindolol is modulated by ␣ 2C -adrenergic receptors for which there is a relatively common (Ϸ10% of the general population) minor polymorphic allele that leads to a 4 -amino acid deletion in the receptor protein, resulting in nearly total loss of function. When this allele is present in either a single (heterozygotes) or double copy, dysregulation of NE release results. This dysregulation leads to a substantial increase in inhibition of NE release of bucindolol. As a result, NE levels precipitously fall to levels below that which can support cardiac function, predisposing the patient to adverse events that cancel the beneficial effects of ␤-blockade. On the other hand, when the major "wild type" allele is present in the homozygous state, bucindolol produces only mild and clinically beneficial degrees of NE lowering. Thus, the use of genetic testing could improve the clinical response to bucindolol, which is a strategy being pursued in the development of this drug.
Conclusions:
In the ␤-Blocker Evaluation of Survival Trial AR polymorphism substudy, the norepinephrine lowering and clinical therapeutic responses to bucindolol were strongly influenced by ␣ 2C receptor genotype. 21
Intramyocardial BNP Gene Delivery Improves Cardiac Function Through Distinct Context-Dependent Mechanisms
Summary: Heart failure is one of the most common causes of cardiovascular morbidity and mortality, and its prevalence is rapidly increasing as the mean age of the population advances. Despite optimal treatment with existing drugs, the prognosis of heart failure remains poor, and thus therapeutic strategies designed to specifically attenuate the myocardial remodeling process would represent a promising new approach to treat patients with heart failure. In the present study, the authors report that B-type natriuretic peptide (BNP) gene delivery may be a potential new therapy after infarction. Their studies indicate that BNP gene delivery has unique pleiotropic, context-dependent, favorable actions on cardiac function because (1) local BNP gene delivery into the rat adult heart improved left ventricular contractility during the remodeling process both after infarction and in response to pressure overload; (2) in healthy heart, local increase in left ventricular BNP peptide levels by gene delivery was antifibrotic and angiogenic without affecting systolic function; and (3) the favorable effect of BNP on cardiac function after infarction but not in angiotensin II-induced hypertension was associated with normalization of SERCA2 expression and phosphorylation of phospholamban. Finally, the results suggest that myocardial BNP acts locally as a key mechanical load-activated regulator of angiogenesis and fibrosis. It would be attractive to develop novel pharmacological therapies for the enhancement of BNP function selectively in the heart and to investigate whether phosphodiesterase inhibitors or novel direct guanylate cyclase activators modify the favorable antifibrotic and angiogenic effects of BNP gene delivery on cardiac function.
Conclusions:
Local intramyocardial BNP gene delivery improves cardiac function and attenuates adverse postinfarction and angiotensin II-induced remodeling. These results also indicate that myocardial BNP has pleiotropic, context-dependent, favorable actions on cardiac function and suggest that BNP acts locally as a key mechanical load-activated regulator of angiogenesis and fibrosis. 22
Nuclear Effects of G-Protein Receptor Kinase 5 on Histone Deacetylase 5-Regulated Gene Transcription in Heart Failure
Summary: The Leu41 polymorphic variant of G-protein receptor kinase (GRK) 5 is associated with improved outcomes in heart failure and hypertension. Together with its role in ␤-adrenergic receptor desensitization, GRK5 is localized to the nucleus and has been postulated to modulate gene transcription in heart failure models. In these studies, the authors demonstrate that class II histone
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Circulation: Heart Failure Topic Review e37 deacetylase (HDAC) 5 content in the nucleus is increased by signaling through Gq. Both Gln41 and Leu41 variants of GRK5 are equally able to localize to the nucleus and phosphorylate HDAC5, leading to its export from the nucleus and consequent derepression of gene transcription. Using next-generation transcriptomic profiling, the authors demonstrate that GRK5 is able to normalize the expression of a subset of genes downregulated in response to pathological Gq signaling. Therefore, the authors propose that GRK5 may act to protect against heart failure decompensation, both by its actions on ␤-adrenergic receptors and by its action on gene transcription.
Conclusions: GRK5 is a transcriptional modifier of a subset of G␣q-downregulated genes, acting in opposition to the pathological effects of G␣q and normalizing levels of these transcripts. This transcriptional coregulator effect may act in concert with ␤-adrenergic receptor desensitization to protect against heart failure decompensation. 23
Delta-Sarcoglycan Gene Therapy Halts Progression of Cardiac Dysfunction, Improves Respiratory Failure, and Prolongs Life in Myopathic Hamsters
Summary: Previous trials of gene therapy (GT) in animals with genetic myopathy have focused on preventing the development of cardiomyopathy. The present experiment in BIO14.6 myopathic hamsters concerns the effects of GT, using a serotype-9 adenoassociated viral vector carrying the ␦-sarcoglycan gene (which is defective in this animal) attached to a muscle-specific promoter relatively late, when cardiac and skeletal muscle dysfunction is well established. Late GT in these hamsters arrested the progression of cardiac dysfunction and heart failure, normalized respiratory function, and prolonged the lifespan of treated animals. It is currently thought that in about 25% of patients with "idiopathic" cardiomyopathy the cause is genetic, and those with Duchenne/Becker muscular dystrophy most commonly die of cardiac and/or respiratory failure. Often, both in clinical cases of cardiomyopathy and muscular dystrophy, a genetic cause is not identified early by family studies or genetic screening. The results of this experimental study offer hope that in this setting, if the gene responsible for the cardiac and skeletal myopathy can be identified, GT may delay the progression of cardiac and respiratory dysfunction.
Conclusions: GT was highly effective in BIO14.6 hamsters even when given in late-stage disease, a finding that may carry implications for the future treatment of hereditary cardiac and muscle diseases in humans. 24 
Changes in Ion Channel Gene Expression Underlying Heart Failure-Induced Sinoatrial Node Dysfunction
Summary: It is estimated that Ͼ20 million people have heart failure (HF) worldwide, and bradyarrhythmias account for about half of the sudden deaths of patients with HF. Consistent with the high incidence of bradyarrhythmic deaths, HF is known to cause dysfunction of the cardiac conduction system, including the sinoatrial node (SAN). The dysfunction of the SAN is likely to be the result of a remodeling of the ion channels and related proteins responsible for the pacemaker activity of the SAN, and the aim of the study was to investigate this. HF was induced in rats by the ligation of the proximal left coronary artery. In the HF animals, there was an increase in the left ventricular diastolic pressure and a decrease in the left ventricular systolic pressure and SAN dysfunction, the intrinsic heart rate was reduced, and the corrected SAN recovery time was increased. Quantitative polymerase chain reaction was used to measure gene expression in the SAN and surrounding atrial muscle.
There was a widespread remodeling of ion channels; gap junction channels; calcium-, sodium-, and proton-handling proteins; and receptors in the SAN. The decrease of the intrinsic heart rate can be explained by an upregulation of various potassium channels. Curiously, the atrial muscle was much less sensitive to HF. Of the 91 genes studied, 41% changed in the SAN, but only 7% changed in the atrial muscle. The elucidation of the mechanisms responsible for SAN dysfunction in HF opens the way to the development of new treatments.
Conclusions: SAN dysfunction is associated with HF and is the result of an extensive remodeling of ion channels; gap junction channels; Ca 2ϩ -, Na ϩ -, and H ϩ -handling proteins; and receptors in the SAN. 25
Gene Delivery of Sarcoplasmic Reticulum Calcium ATPase Inhibits Ventricular Remodeling in Ischemic Mitral Regurgitation
Summary: Myocardial infarction also causes ischemic mitral regurgitation (MR) by altering ventricular geometry and function, thus doubling the risk of death. The authors have demonstrated that MR worsens remodeling after myocardial infarction and that early correction reverses remodeling. The sarcoplasmic reticulum calcium ATPase pump (SERCA) is downregulated in this process. The authors hypothesized that upregulating SERCA might inhibit remodeling in their animal model. Gene delivery was performed percutaneously with an adeno-associated virus carrying SERCA or a reporter gene in controls. After 2 weeks, an apical myocardial infarction was created, and MR-type flow was induced. At 3 months, the SERCA group had well-maintained left ventricular contractility and a rise in antiapoptotic and prohypertrophic pathways. Upregulating SERCA therefore inhibited MR-induced post-myocardial infarction remodeling in this model and thus may constitute a useful approach to reduce the vicious circle of remodeling in ischemic MR. Specifically, therapies aimed at improving the calcium cycling apparatus in the cardiac cell may be promising approaches to inhibit remodeling, potentially reducing its associated morbidity and mortality.
Conclusions: In this controlled model, upregulating SERCA2a induced better function and lesser remodeling, with improved contractility, smaller volume, and activation of prohypertrophic/antiapoptotic pathways. Although caspase-3 remained activated in both groups, SERCA2a sheep had increased molecular antiremodeling "tone." The authors therefore conclude that upregulating SERCA2a inhibits MR-induced post-MI remodeling in this model and thus may constitute a useful approach to reduce the vicious circle of remodeling in ischemic MR. 26
Functional Adiponectin Resistance at the Level of the Skeletal Muscle in Mild to Moderate Chronic Heart Failure
Summary: Skeletal muscle dysfunction is an important determinant of exercise intolerance in patients with chronic heart failure (CHF). In addition to structural and functional abnormalities, changes involving mitochondrial bioenergetics explain the energetic deficit that characterizes skeletal muscles of these patients. Recently, insulin resistance has gained attention as a relevant pathophysiological mechanism in CHF. Adiponectin is an insulin-sensitizing cytokine, promoting the uptake and oxidation of glucose and fatty acids at the level of the skeletal muscle. High circulating adiponectin levels infer poor prognosis in patients with CHF. However, the regulation of the local adiponectin system at the level of the skeletal muscle and its metabolic consequences in this population have not been explored previously. In this study, comparison of skeletal muscle biopsies from healthy subjects and patients with CHF showed that in the latter, mRNA expression for adiponectin was significantly increased, whereas it was reduced for the main adiponectin receptor. In addition to these local changes, deactivation of the peroxisome proliferatorsactivated receptor-␣/AMP-activated protein kinase pathway and downregulation of several target genes involved in both fatty acid e38 Circ Heart Fail March 2012 oxidation and glucose metabolism were shown. Taken together, these findings suggest the existence of a functional adiponectin resistance. Hence, increased circulating adiponectin concentrations probably represent a protective mechanism to counteract adiponectin resistance and the compromised energy metabolism. The inverse relationship between exercise parameters and circulating adiponectin in patients with CHF supports the assertion that the more the skeletal muscle metabolism is disturbed, the higher the adiponectin compensatory mechanism is activated.
Conclusions: Despite increased adiponectin expression in the skeletal muscle, patients with CHF are characterized by downregulation of AdipoR1 that is most probably linked to deactivation of the PPAR-␣/AMP-activated protein kinase pathway. These facts suggest functional adiponectin resistance at the level of the skeletal muscle in CHF. 27
Toll-Like Receptor-Mediated Inflammatory Signaling Reprograms Cardiac Energy Metabolism by Repressing Peroxisome Proliferator-Activated Receptor-␥ Coactivator-1 Signaling
Summary: Sepsis syndrome is a significant cause of morbidity and mortality worldwide. Myocardial dysfunction is a common feature of this condition and is a predictor of worse clinical outcome. At present, there are no specific therapeutic targets for the cardiodepressant effects of systemic inflammation. Attempts to disrupt the early inflammatory phase of sepsis have been unsuccessful at improving outcomes. Therefore, targeting pathological pathways downstream of the inflammatory cascade, such as cellular metabolic derangements, has the potential to be a more fruitful approach. Previous studies have suggested that organ failure in sepsis may be related to dysfunctional mitochondrial metabolism, leading to a reduction in energy production and an increase in reactive oxygen species generation. The authors demonstrate that systemic inflammation activated by bacterial lipopolysaccharides reduces oxidative metabolism in the heart. This metabolic shift is associated with deactivation of the peroxisome proliferator-activated receptor-␥ coactivator-1 (PGC-1) transcriptional circuit, a key regulator of mitochondrial function. By using both cell culture and in vivo approaches, the authors demonstrate that reactivation of PGC-1 during acute inflammation restores the expression of its downstream gene targets, reverses the decline in fatty acid oxidation, reduces oxidative stress, and improves cardiac function. These data suggest that the PGC-1 axis represents a novel therapeutic target for sepsis-induced cardiac dysfunction.
Conclusions: Lipopolysaccharide triggers cardiac energy metabolic reprogramming through suppression of PGC-1 coactivators in the cardiac myocyte. Reactivation of PGC-1␤ expression can reverse the metabolic and functional derangements caused by lipopolysaccharide-toll-like receptor 4 activation, identifying the PGC-1 axis as a candidate therapeutic target for sepsis-induced heart failure. 28
Impaired Mitochondrial Biogenesis Precedes Heart Failure in Right Ventricular Hypertrophy in Congenital Heart Disease
Summary: Right ventricular (RV) pressure and/or volume overload represents a common clinical scenario in patients with congenital heart disease (CHD). Physiological mechanisms can compensate even for decades. However, chronic maintenance of this overload may lead to the development of severe ventricular hypertrophy, dilatation and dysfunction, ventricular arrhythmias, and ultimately, heart failure. Several clinical reports indicate that when severe RV dilatation, dysfunction, and/or arrhythmias occur, the outcomes of these patients are poor even if a successful surgery with relief of the hemodynamic burden is carried out. Nevertheless, the appropriate timing for intervention is not standardized. This study demonstrates an impairment in mitochondrial biogenesis in patients with CHD and chronic RV overload. Specifically, the authors observed a decrease in the quantity of mitochondrial DNA in myocardial samples obtained from patients with CHD undergoing cardiac surgery when compared with control subjects. This decrease was seen early and progressed during the transition from compensated RV overload to decompensated RV failure. The decrease in mitochondrial DNA was more pronounced in patients with significantly elevated RV systolic pressure. The results suggest that in patients with CHD and RV overload, cellular changes start early, before the development of clinical signs or symptoms of heart failure. These changes were more marked in patients with high RV pressures. Prompt intervention to relieve the hemodynamic load on the RV may improve outcomes in this challenging population.
Conclusions: Impaired mtDNA replication causes early and progressive depletion of mtDNA in the RV of the patients with CHD during the transition from hypertrophy to failure. Decreased mtDNA content probably is a sensitive marker of mitochondrial injury in this patient population. 29
Ginseng Inhibits Cardiomyocyte Hypertrophy and Heart Failure Via NHE-1 Inhibition and Attenuation of Calcineurin Activation
Summary: Heart failure is a major cause of hospitalization and is associated with high financial costs and societal burden. Cardiac hypertrophy and myocardial infarction are major risk factors for the development of heart failure. In recent years, there has been growing interest in botanicals as alternative medicines for cardiovascular disease. Ginseng is a popular traditional herbal medicine and has been widely used to treat cardiovascular diseases for thousands of years in Asia. Despite increasing interest in ginseng in Western societies, its efficacy and mechanism of action are poorly understood. The authors sought to understand the effect of ginsenosides on cardiomyocyte hypertrophy and myocardial infarction-induced heart failure. In in vitro studies, the authors showed that ginsenosides were able to attenuate cardiomyocyte hypertrophy. Further studies revealed that the antihypertrophic effect of ginsenosides was mediated by inhibiting NHE-1 activity and blocking calcium-mediated signaling, which is evidenced by decreased intracellular calcium levels, calcineurin activity, and NFAT3 translocation. In support of in vitro findings, the authors' in vivo studies demonstrated that oral administration of ginsenosides prevented the progression of heart failure by reducing postinfarction myocardial hypertrophy and improving hemodynamics. Although results from animal studies must be interpreted cautiously, the authors' findings support the development of ginsenosides as potential therapeutics for the treatment of cardiac diseases and demonstrate the cellular bases for these actions.
Conclusions: Taken together, these results demonstrate a robust antihypertrophic and antiremodeling effect of ginseng, which is mediated by inhibition of NHE-1-dependent calcineurin activation. 30
Analysis of Metabolic Remodeling in Compensated Left Ventricular Hypertrophy and Heart Failure
Summary: Congestive heart failure (CHF) is associated with a significant change in energy metabolism of the heart, and this alteration has been hypothesized to be important in the progression of CHF. Because treatment that improves the prognosis of patients with CHF, such as with ␤-adrenergic receptor blockers or angiotensin-converting enzyme inhibitors, is energy-sparing, it is hoped that modulation of cardiac energy metabolism may ameliorate CHF. The authors analyzed cardiac energy metabolism in Dahl salt-sensitive rats that were fed a high-salt diet, which showed a transition from compensated left ventricular hypertrophy to CHF. Left ventricular hypertrophy or CHF was associated with a distinct change in the metabolic profile of the heart. Glucose uptake increased and fatty acid uptake decreased in CHF. On comprehensive metabolome analysis that simultaneously measured the levels of multiple metabolites in heart tissue, the pentose phosphate pathway that regulates the cellular redox state was found to be activated in CHF. Dichloroacetate, a compound known to enhance glucose oxidation, increased glucose uptake and the energy reserve and improved cardiac function and survival. Dichloroacetate also activated the pentose phosphate pathway, decreased oxidative stress, and prevented cell death of cultured cardiomyocytes. Thus, increased glucose metabolism in CHF is likely to act as a protective mechanism by increasing the energy reserve and decreasing oxidative stress via pentose phosphate pathway activation. In summary, modulating the energy metabolism of the heart is likely to be a promising modality of CHF treatment.
Conclusions: Left ventricular hypertrophy or CHF is associated with a distinct change in the metabolic profile of the heart. Dichloroacetate attenuated the transition associated with increased energy reserves, activation of the pentose phosphate pathway, and reduced oxidative stress. 31
Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy
Summary: Myocardial late gadolinium enhancement (LGE) on contrast-enhanced MRI of patients with hypertrophic cardiomyopathy has been suggested to represent intramyocardial fibrosis. The authors explored the relation between LGE among 424 patients with hypertrophic cardiomyopathy and their genetic testing status, presence of severe symptoms, ventricular arrhythmias, or occurrence of sudden cardiac death. Two hundred thirty-nine patients (56%) had
LGE on contrast-enhanced MRI, ranging from 0.4 -65% of the left ventricle. Gene-positive patients were more likely to have LGE. The frequencies of New York Heart Association class Ն3 dyspnea and angina class Ն3 were similar in patients with and without LGE.
LGE-positive patients were more likely to have episodes of nonsustained ventricular tachycardia and higher frequency of ventricular extrasystoles per 24 hours. During a mean follow-up of almost 4 years, sudden cardiac death occurred in 4 patients, and an additional 4 patients received appropriate defibrillator discharges. All 8 patients were LGE positive. The association of LGE with events remained significant after controlling for other risk factors. The authors concluded that in patients with hypertrophic cardiomyopathy, the presence of LGE on contrast-enhanced MRI was common and more prevalent among gene-positive patients.
LGE was not associated with severe symptoms, but LGE was strongly associated with surrogates of arrhythmia and remained a significant associate of subsequent sudden cardiac death and/or implantation of cardioverterdefibrillator discharge. If replicated, LGE may be considered an important risk factor for sudden death in patients with hypertrophic cardiomyopathy.
Conclusions:
In patients with hypertrophic cardiomyopathy, the presence of LGE on contrast-enhanced MRI was common and more prevalent among gene-positive patients.
LGE was not associated with severe symptoms. However, LGE was strongly associated with surrogates of arrhythmia and remained a significant associate of subsequent sudden cardiac death and/or implantable cardioverterdefibrillator discharge after controlling for other variables. If replicated, LGE may be considered an important risk factor for sudden death in patients with hypertrophic cardiomyopathy. 32
Effects of Continuous-Flow Versus Pulsatile-Flow Left Ventricular Assist Devices on Myocardial Unloading and Remodeling
Summary: Continuous-flow left ventricular assist devices (LVAD) are increasingly used for patients with end-stage heart failure.
Continuous-flow devices have the advantage of smaller size, longer durability, higher energy efficiency, less thrombogenicity, and less surgical trauma compared with the previously used pulsatile-flow LVADs. The authors investigated the effects of ventricular unloading using continuous-flow versus pulsatile-flow LVADs on myocardial structure and function. They analyzed 31 patients with a pulsatile-flow LVAD and 30 patients with a continuous-flow LVAD. Echocardiographic parameters of systolic and diastolic function improved more in patients with pulsatile-flow LVAD compared with those with continuous-flow LVAD. Myocardial gene expression of extracellular matrix markers and brain natriuretic peptide as well as serum levels of brain natriuretic peptide, metalloproteinase-9, and tissue inhibitor of metalloproteinase-4 were more significantly reduced in patients with pulsatile-flow LVAD than those with continuous-flow LVAD. This study is the first systematic assessment comparing pulsatile and nonpulsatile VADs in relation to these markers of myocardial reverse remodeling and extracellular matrix turnover. These observations demonstrate a more profound unloading of the failing myocardium by pulsatile-flow devices than by the continuous-flow devices currently used. These differences may be important if assist devices are implanted with the hope of supporting cardiac recovery.
Conclusions: Mechanical unloading of the failing myocardium using pulsatile devices is more effective as indicated by echocardiographic parameters of systolic and diastolic LV function as well as dynamics of brain natriuretic peptide and extracellular matrix markers. Therefore, specific effects of pulsatile mechanical unloading on the failing myocardium may have important implications for device selection, especially for the purpose of bridge-to-recovery in patients with advanced heart failure. 33
Chronic Electric Stimulation of the Carotid Sinus Baroreflex Improves Left Ventricular Function and Promotes Reversal of Ventricular Remodeling in Dogs With Advanced Heart Failure
Summary: Despite major advances in the development of new drugs for the treatment of chronic heart failure, the mortality and morbidity from this disease syndrome remain unacceptably high. In some patients, the use of life-saving standard pharmacological therapy such as angiotensin-converting enzyme inhibitors, ␤-adrenergic receptor blockers, and aldosterone antagonists is suboptimal because of poor tolerability. Even in patients with heart failure who have over the years tolerated and benefited from these pharmacological therapies, a time is reached when their effectiveness wanes and symptomatology from the disease increases, and new therapeutic interventions are needed. In the present study, the authors tested a novel device-based therapy that can potentially be used in the treatment of such patients. The approach, termed chronic activation of the carotid sinus baroreflex, which acts via electric stimulation of the carotid sinus nerve, was tested as monotherapy in dogs with experimental heart failure. Compared with no therapy at all, chronic carotid sinus baroreflex treatment resulted in improved left ventricular systolic and diastolic function and attenuation of left ventricular remodeling. The improvement in ventricular function was associated with reduced left ventricular filling pressure, reduced left ventricular size, and lowering of heart rate, along with normalization of components of the renin-angiotensin-aldosterone system, the sympathetic nervous system, and the nitric oxide signaling pathway. All of these benefits argue in favor of carotid sinus baroreflex therapy, which is likely to provide benefit to patients with advanced chronic heart failure. Translation of the results of this study to the clinical setting, however, must be used with care, given that the experimentation was conducted in the absence of standard background medical therapy, as would certainly be the case in patients.
Conclusions:
In dogs with advanced heart failure, carotid sinus baroreflex activation improves global left ventricular function and partially reverses left ventricular remodeling both globally and at cellular and molecular levels. 34
Chromogranin B in Heart Failure: A Putative Cardiac Biomarker Expressed in the Failing Myocardium
Summary: The cardiac biomarkers used routinely in clinical practice today are proteins specific to the diseased myocardium, either released during cell necrosis (cardiac-specific troponins) or secreted secondary to cardiomyocyte strain (B-type natriuretic peptide). However, there is still a need for markers reflecting other pathophysiological processes in heart disease. The authors have identified chromogranin B (CgB) as a protein that is closely regulated in the left ventricle in heart failure (HF), whereas production was unaltered in other tissues investigated. Circulating levels of CgB were also elevated in patients with HF compared with healthy control subjects, and levels increased in proportion to severity of HF as evaluated by New York Heart Association functional class. Plasma CgB levels correlated only modestly with B-type natriuretic peptide and chromogranin A (CgA) levels, another granin protein and novel HF biomarker, indicating that CgB is regulated by other mechanism than B-type natriuretic peptide and CgA in HF. As CgB is closely associated with Ca 2ϩ signaling, CgB could potentially be a marker providing information on processes currently not reflected by established HF biomarkers. However, the role of CgB in HF development and as a cardiac biomarker still requires additional experimental and clinical studies before clinical utility may be established.
Conclusions: B production is increased and regulated in proportion to disease severity in the left ventricle and circulation during HF development. 35 
Osteopontin Expression in Cardiomyocytes Induces Dilated Cardiomyopathy
Summary: Osteopontin (OPN) is a chemokine expressed in chronic inflammatory and autoimmune diseases involved in immune cell recruitment and type 1 cytokine expression. It is also involved in tissue remodeling. Heart remodeling in response to chronic changes in hemodynamic load is a key process in the development of heart failure. It is mostly characterized by an increase in heart chambers' volume and myocardial mass whose evaluation by various imaging techniques is of first importance for the management of patients and estimation of the progression of the disease with time and of prognosis. It is also a central therapeutic target. Changes in extracellular matrix structure and composition in the remodeling process are now well established. Its components include matricellular proteins like OPN with regulatory functions, whose expression is almost absent after birth but can be activated after tissue injury and participate to tissue remodeling. For these reasons, circulating concentration of OPN is now under consideration for use as a biomarker for the prognosis of heart failure. In this study, the authors suggest a potent causative/triggering role for OPN in the development of dilated cardiomyopathy. It shows that heart-derived OPN may trigger heart failure and induce a hypokinetic myocardiopathy associating conduction defects and early signs of myocarditis preceding left ventricular dilation and death. Therefore, this study suggests that OPN may be used as a diagnostic tool and a potential therapeutic target to limit left ventricular remodeling in chronic myocarditis. Inhibition of OPN expression by vitamin D analogs could be tested in this context.
Conclusions:
These data show that OPN expression in the heart induces in vivo T-cell recruitment and activation leading to chronic myocarditis, the consequence of which is myocyte destruction and hence, dilated cardiomyopathy. Thus, OPN might therefore constitute a potential therapeutic target to limit heart failure. 36
Heart Failure-Associated Changes in RNA Splicing of Sarcomere Genes
Summary: Changes in gene expression accompany and contribute to heart failure. These gene expression changes have been documented at the whole-gene level using microarray-based, genome-wide expression profiling approaches. However, global changes in mRNA splicing in heart failure have not been previously studied. The authors use a microarray that individually measures expression of each known or putative exon and reverse transcription polymerase chain reaction assays to examine splicing changes that accompany heart failure. They found that broad changes in mRNA splicing occur in the failing heart. Many of these changes were indicative of decreased efficiency of mRNA splicing, and among the affected genes, there were several sarcomere genes. These splicing changes also were observed in hypertrophied myocardium with preserved systolic function, suggesting that the splicing changes may occur before the onset of overt heart failure. The splicing changes were characteristic of diseased myocardium. A prediction model using the splicing of 3 sarcomere genes discriminated failing from nonfailing hearts with 98% accuracy, providing proof of principle that splicingbased biomarkers may provide diagnostic and prognostic information on patients with heart disease. Future studies will be needed to prospectively evaluate the value of splicing-based myocardial biomarkers in individualizing therapy in heart failure. Future work also will be needed to determine whether changes in RNA splicing are functionally important in the pathogenesis of heart disease and whether targeted modulation of splicing is a useful therapeutic strategy for heart failure.
Conclusions: These data indicate that mRNA splicing is broadly altered in human heart disease and that patterns of aberrant RNA splicing accurately assign samples to control or disease classes. 37
Reciprocal Transcriptional Regulation of Metabolic and Signaling Pathways Correlates With Disease Severity in Heart Failure
Summary: Congestive heart failure (HF) is a leading cause of morbidity and mortality worldwide. Despite phenotypic similarities characterized by ventricular dilatation and reduced contractility, the extent of common and divergent gene expression between different forms of HF remains a matter of intense debate. Focusing on molecular pathways, the authors demonstrate that myocardial gene expression in 28 experimental models of nonischemic (pressure overload, tachypacing, chronic isoproterenol infusion, Chagas disease, and transgenic HF models) and ischemic HF is consistently characterized by downregulation of major metabolic pathways and concomitant upregulation of cell signaling pathways, thus recapitulating a fetal gene expression program. In contrast to this uniform transcriptional response observed in animal models, human HF microarray studies displayed a greater variability, with some studies even showing a reversed pattern. The reasons for this divergence are almost certainly multifactorial and include the lack of true nonfailing human control tissue (significant cardiac disease in nonfailing samples and differences in tissue preservation techniques leading to a fetal gene expression pattern) and the effect of medication, namely angiotensin-converting enzyme inhibitors and ␤-blockers, partially reversing the fetal gene expression pattern in failing samples. These results highlight the difficulties of interpreting results from "realworld" human clinical samples and stress the importance of wellcontrolled animal models to elucidate disease mechanisms. The authors conclude that irrespective of the etiology of HF, gene expression in failing myocardium is characterized by downregulation of metabolic transcripts and concomitant upregulation of cell signaling pathways, thus providing a unifying concept for the heterogeneous transcriptional response observed in phenotypically similar models of HF.
Conclusions: Irrespective of the etiology, gene expression in failing myocardium is characterized by downregulation of metabolic tran-scripts and concomitant upregulation of cell-signaling pathways. Gene expression changes along this metabolic-signaling axis in mammalian myocardium are a consistent feature in the heterogeneous transcriptional response observed in phenotypically similar models of HF. 38
Common Variants in HSPB7 and FRMD4B Associated With Advanced Heart Failure
Summary: Heart failure is a common, heterogeneous disorder that leads to substantial morbidity and mortality in the developed world. Although population-based studies have demonstrated a genetic component to common forms of heart failure, specific risk loci have been difficult to identify. In this study, the authors tested the broad hypothesis that common genetic variation in Ϸ2000 candidate genes of known importance to cardiovascular biology contribute to heart failure risk. They found that common single-nucleotide polymorphisms in HSPB7 (rs1738943) and FRMD4B (rs6787362) were associated with advanced heart failure in 2 Caucasian referral populations but not in African Americans. For both single-nucleotide polymorphisms, the minor allele was less frequent in cases than in controls, indicating that patients who carry the minor allele are at lower risk for heart failure, though the magnitude of these changes in risk are too small to be applied clinically. Thus, these findings identify HSPB7 and FRMD4B as novel heart failure susceptibility loci and should stimulate efforts to identify the underlying mechanisms.
Conclusions: These findings identify regions containing HSPB7 and FRMD4B as novel susceptibility loci for advanced heart failure. More broadly, in an era of genome-wide association studies, the authors demonstrate how knowledge of candidate genes can be leveraged as a complementary strategy to discern the genetics of complex disorders. 39
The S1103Y Cardiac Sodium Channel Variant Is Associated With Implantable Cardioverter-Defibrillator Events in Blacks With Heart Failure and Reduced Ejection Fraction
Summary: Sudden cardiac death (SCD) risk stratification for primary prevention implantable cardioverter-defibrillators (ICDs) is currently limited to reduced ejection fraction, yet the majority of people having SCD do not meet the criteria, nor do the majority of patients receiving primary prevention ICDs derive benefit from the device. In this report, the authors show that the S1103Y variant in the cardiac sodium channel gene, present in approximately 13% of blacks, is associated with a 3-to 4-fold increase in ICD "events" in patients with reduced ejection fraction. This genetic association is independent of traditional clinical risk factors for SCD. Identifying patients with this variant may potentially improve risk stratification for SCD in blacks, in whom there is a high prevalence of this variant.
Conclusions: This is the first report that the S1103Y variant is associated with a higher incidence of ventricular arrhythmias in blacks with heart failure and reduced ejection fraction. 40
Association of Genome-Wide Variation With the Risk of Incident Heart Failure in Adults of European and African Ancestry: A Prospective Meta-Analysis From the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium
Summary: Genetic factors contribute to heart failure (HF) onset and, to date, most approaches to identify genetic variants associated with HF risk have relied on candidate genes. No large-scale genome-wide investigation of HF risk has been published. The authors investigated the association of Ϸ2.5 million single-nucleotide polymorphisms with incident HF by meta-analyzing data from 4 community-based prospective cohorts: the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Framingham Heart Study, and the Rotterdam Study. Among 20 926 European-ancestry participants with 2526 incident HF events, the authors identified 1 locus with a single-nucleotide polymorphism, whose probability value (1.4ϫ10 Ϫ8 ) exceeded the genome-wide statistical significance threshold of 5ϫ10 Ϫ7 and was associated with a 53% increase in HF risk. Among 2895 African-ancestry participants who had 466 incident events, the authors identified 1 locus with a single-nucleotide polymorphism, whose probability value (6.7ϫ10 Ϫ8 ) exceeded the genome-wide statistical significance and was associated with a 46% increase in HF risk. They identified an additional 14 loci in European-ancestry and Africanancestry participants that were marked by high-signal single-nucleotide polymorphisms with a probability value Ͻ1.0ϫ10 Ϫ5 . For most loci, risk estimates were modest and did not seem to differ in subjects without a myocardial infarction preceding HF onset. The results suggest that there may be several genomic regions associated with new-onset HF in older adults and support the hypothesis that common genetic variation, regardless of the clinical mechanism responsible for reduced cardiac output in HF, contributes to the risk.
Conclusions:
The authors identified 2 loci that were associated with incident HF and exceeded genome-wide significance. The findings merit replication in other community-based settings of incident HF. 41
Genomic Variation Associated With Mortality Among Adults of European and African Ancestry With Heart Failure: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium
Summary: This study investigated 2526 incident heart failure (HF) cases of European ancestry and 466 incident HF cases of African ancestry for an association between genome-wide variation and all-cause mortality. One variant in the CKLF-like MARVEL transmembrane domain containing 7 (CMTM7) genes was significantly associated with all-cause mortality in individuals of European ancestry with HF. CMTM7 is 1 of several chemokine-like factor genes clustered in the same region on chromosome 3p22. These results suggest that chemokines may play a role in survival of patients with HF. No genomic variation was significantly associated with mortality in individuals with HF of African ancestry. Future studies of this type may identify genes that lead to an improved understanding of HF pathophysiology and treatment of the disease. These findings warrant additional investigation, including replication, in other studies of HF.
Conclusions: This study identified a novel locus associated with all-cause mortality among individuals of European ancestry with HF. This finding warrants additional investigation, including replication, in other studies of HF. 42
Molecular Genetic and Functional Characterization Implicate Muscle-Restricted Coiled-Coil Gene (MURC) as a Causal Gene for Familial Dilated Cardiomyopathy
Summary: Heart failure is a major cause of mortality and morbidity. Genetic mutations are important causes of susceptibility to heart failure. Familial dilated cardiomyopathy (DCM) is a classic form of systolic heart failure caused by genetic mutations. The known causal genes for DCM typically code for sarcomere and cytoskeletal proteins. Prompted by the experimental data, which implicate Muscle-Restricted Coiled-Coil (MURC) in regulating cardiac function, the authors investigated the causal role of the MURC gene in DCM. The authors sequenced the protein coding regions of MURC in 383 probands with DCM, 307 with hypertrophic cardiomyopathy, and 509 healthy control subjects. They found 6 missense mutations that were present only in DCM patients and were absent in control subjects. Two of these mutations segregated with inheritance of DCM in small families. One mutation recurred in 3 independent probands, including 1 proband who also had another mutation in the ␣-tropomyosin gene. The authors also found 1 deletion mutation in 3 unrelated probands with hypertrophic cardiomyopathy that might be a causative or susceptibility variant. The clinical features associated with MURC mutations included progressive heart failure that often led to heart transplantation, conduction defects, and atrial arrhythmias. Studies in cultured cardiac myocytes showed that the mutations reduced RhoA activity, an important signal transducer in the heart and impaired myocyte hypertrophic response. The authors conclude that MURC probably is a causal gene for DCM. They suggest elucidation of the molecular genetics and pathogenesis of heart failure is an essential step in the ultimate treatment of this potentially deadly disease.
Conclusions: MURC mutations impart loss-of-function effects on MURC functions and probably are causal variants in human DCM. The causal role of a deletion mutation in HCM is uncertain. 43
Familial Aggregation of Left Ventricular Geometry and Association With Parental Heart Failure: The Framingham Heart Study
Summary: Left ventricular (LV) remodeling is a central process in the pathophysiology of heart failure. However, the factors that influence remodeling patterns in individuals remain unclear. Clinical determinants, such as age, sex, blood pressure, and body size, only partially explain the interindividual variability of LV geometry in the population. The authors investigated the role of familial factors by studying a large, 2-generational community-based sample from the Framingham Heart Study undergoing echocardiography in mid to late adulthood. They found strong evidence of concordance of LV geometry among related pairs of individuals within nuclear families (parent-child, sibling-sibling) but not among unrelated spousal pairs. The presence of a family member with abnormal LV geometry was associated with a 20% increased odds of altered LV geometric pattern in the offspring compared with the prevalence in the authors' study population. Specifically, there was a 40% increased odds of eccentric hypertrophy or concentric remodeling and an almost 4-fold increased odds of concentric hypertrophy among family members of individuals with the corresponding abnormal LV geometric pattern. These associations remained significant after accounting for clinical factors known to influence LV geometry. Further, there was an association between parental heart failure and prevalence of eccentric LV geometry in their offspring. These data demonstrate a potential contribution of familial predisposition to patterns of LV remodeling and suggest that familial factors may play a role in adverse LV remodeling and heart failure progression in the community.
Conclusions: This investigation of a 2-generational communitybased sample demonstrates familial aggregation of LV geometry, with the greatest recurrence risk for concentric LV geometry, and establishes an association between eccentric LV geometry and parental HF. 44
Modulation of Mitochondrial Proteome and Improved Mitochondrial Function by Biventricular Pacing of Dyssynchronous Failing Hearts
Summary: One of the limitations of cardiac resynchronization therapy is that 20 -30% of the patients demonstrate little clinical benefit, if any at all. The authors believe that insight regarding the molecular mechanisms that are activated by cardiac resynchronization therapy may provide candidate targets that identify responders to this therapy and that proteomics could help in pinpointing the key proteins in this process and could narrow down the search for pathways that are dysregulated in nonresponders. Additionally, the study explores what the beneficial pathways activated by cardiac resynchronization therapy are in a well-established in vivo model.
Conclusions:
Cardiac resynchronization therapy potently affects both the mitochondrial proteome and the performance associated with improved cardiac function. 45
Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease
Summary: It was recently discovered that small RNAs, called microRNAs, circulate freely and stably in human plasma. This finding has sparked interest in the potential of microRNAs as biomarkers because microRNAs are strongly implicated in cardiovascular disease, and RNA molecules can be detected with high specificity and sensitivity using novel molecular techniques. The authors report profiles of microRNAs in varying cardiovascular disorders: acute myocardial infarction, acute viral myocarditis, diastolic dysfunction, and acute heart failure. Most strikingly, 2 cardiomyocyte-specific microRNAs (miR-208b and miR-499) are markedly elevated in cardiac damage and correlate to circulating levels of troponin T. These findings suggest a potential role for microRNAs as biomarkers in cardiology and mandate subsequent investigations to define their clinical applicability in early detection of myocardial damage.
Conclusions: Cardiac damage initiates the detectable release of cardiomyocyte-specific microRNA-208b and microRNA-499 into the circulation. 46
Genome-Wide Significance and Replication of the Chromosome 12p11.22 Locus Near the PTHLH Gene for Peripartum Cardiomyopathy
Summary: Peripartum cardiomyopathy (PPCM) is an uncommon diagnosis but is often devastating for those it affects: younger women who are in their childbearing years. Although evidence is sparse, risk factors for PPCM and its more heterogeneous relative, pregnancyassociated cardiomyopathy, may include maternal age Ͼ30 years, multiparity, multiple gestation, a history of preeclampsia, use of tocolytics, and African ancestry. Heritable factors may also influence PPCM, and this study reports the discovery and validation of a novel PPCM locus on chromosome 12. Although not located within a classic gene, the implicated single nucleotide polymorphism is near the parathyroid hormone-like hormone gene, which is an excellent candidate gene for PPCM. This discovery may signal important directions for pathophysiologic research of PPCM etiology, while also providing a fertile bed for further genetic association studies of this and other possible causal sequence variants in the genomic region. Additional studies are warranted to evaluate potential clinical applications of these observations.
Conclusions: Genome-wide association with PPCM was discovered and replicated for rs258415 at chromosome 12p11.22 near PTHLH.
This study indicates a role of genetic factors in PPCM and provides a new locus for further pathophysiological and clinical investigation. 47 vanced statistical methods for network analysis of the largest collection of myocardial gene expression data assembled to date, the authors tested a fundamental hypothesis in cardiovascular biology, namely, whether a fetal gene expression program is recapitulated in the failing and hypertrophied adult heart. In doing so, the authors identified networks of genes in developing, failing, and hypertrophied myocardium that may be important to both the developing and failing heart. Limited evidence was found for a single, coordinated program of gene expression shared between the developing and failing heart. However, the definition of higher-order organization of the myocardial transcriptome and novel potential transcriptional regulators enriches our understanding of the genomic basis of myocardial development and disease and may someday lead to therapeutic interventions targeting maladaptive cardiac stress responses.
Conclusions: Network modeling allows systems analysis of cardiovascular development and disease. Although the authors did not find evidence for a global coordinated program of fetal gene expression in adult myocardial adaptation, this analysis revealed specific gene expression modules active during both development and disease and specific candidates for their regulation. 48
Sarcomere Gene Mutations in Isolated Left Ventricular Noncompaction Cardiomyopathy Do Not Predict Clinical Phenotype
Summary: Left ventricular noncompaction of the myocardium (LVNC) is a cardiomyopathy with a genetic etiology and autosomal-dominant transmission is common. The morphological echocardiographic characteristics include a severely thickened, 2-layered myocardium, numerous prominent trabeculations, and deep intertrabecular recesses. The clinical features range from asymptomatic individuals to symptomatic patients with progressive deterioration of cardiac function; thrombembolic events; and arrhythmias, including sudden cardiac death. LVNC is genetically heterogeneous, and prior reports indicate that mutations in genes encoding sarcomere proteins are associated with LVNC. In the present study, the authors evaluated the potential clinical impact of genetic analysis of sarcomere genes in patients with isolated LVNC. They describe mutations in cardiac myosin-binding protein C (MYBPC3) and ␣-tropomyosin (TPM1) in a cohort of unrelated adult probands with isolated LVNC. The mutations in MYBPC3 and TPM1and in 6 other previously reported sarcomere genes in this cohort resulted in a total of 18 (29%) heterozygous mutations in 63 probands. ␤-Myosin heavy chain (MYH7) was the most prevalent disease gene, accounting for 13% of cases, followed by MYBPC3 (8%). Although mutations in sarcomere genes account for a significant proportion of cases of isolated LVNC, patients who are mutation positive could not be distinguished from those who are mutation negative by their clinical characteristics. However, the authors provide insight into how mutations of different sarcomere genes lead to diverse clinical phenotypes, with implications for diagnosis, genetic testing, and follow-up. Genetic testing of sarcomere genes is a valuable diagnostic tool for the probands and their relatives who may be at high risk of inheriting the cardiomyopathy.
Conclusions:
Mutations in sarcomere genes account for a significant (29%) proportion of cases of isolated LVNC in this cohort. The distribution of disease genes confirms genetic heterogeneity and opens new perspectives in genetic testing in patients with LVNC and their relatives at high risk of inheriting the cardiomyopathy. The presence or absence of a sarcomere gene mutation in LVNC cannot be related to the clinical phenotype. 49
Homozygosity Mapping and Exome Sequencing Reveal GATAD1 Mutation in Autosomal Recessive Dilated Cardiomyopathy
Summary: Recognition of idiopathic dilated cardiomyopathy (DCM) as a heritable disorder in 25-50% of patients with this condition has provided a rationale for screening echocardiography in at-risk relatives to detect presymptomatic disease. Furthermore, familial DCM has been the impetus for human genetics investigations to uncover the molecular underpinnings of myopathic heart failure. DCM is now well established as a genetically heterogeneous disorder, yet mutations in identified genes are estimated to account for only one-third of cases. Beyond targeted hypothesis-based screening of candidate genes, completion of the Human Genome Project and technological advances in DNA analysis have enabled powerful whole-genome approaches that overcome inherent limitations of traditional disease gene discovery. These approaches can, in fact, uncover unanticipated DCM genes and new insights into the pathobiology of heart failure. In this study, the authors identified and phenotypically characterized a consanguineous family with nonsyndromic DCM segregating as an autosomal recessive trait. Exome sequencing, providing comprehensive sequence data for proteincoding regions of virtually all genes, and genome-wide locus mapping, providing a positional filter for the large number of identified genetic variants, were used as synergistic strategies to identify a pathogenic homozygous mutation in GATAD1. Previous work has shown that GATAD1 binds to histones, the fundamental building blocks of chromatin that package and condense DNA and serve as targets for posttranslational modification and regulation of gene expression. Consistent with murine DCM caused by genetic disruption of histone deacetylases, the data implicate an inherited basis for epigenetic perturbation as an underlying basis for human heart failure.
Conclusions: Linkage analysis and exome sequencing were used as synergistic genomic strategies to identify GATAD1 as a gene for AR DCM. GATAD1 binds to a histone modification site that regulates gene expression. Consistent with murine DCM caused by genetic disruption of histone deacetylases, the data implicate an inherited basis for epigenetic dysregulation in human heart failure. 50
Prevalence of Desmosomal Protein Gene Mutations in Patients With Dilated Cardiomyopathy
Summary: Idiopathic dilated cardiomyopathy (DCM) is defined by the presence of a dilated and poorly functioning left ventricle in the absence of abnormal loading conditions or ischemic heart disease sufficient to cause global systolic impairment. A large number of cardiac and systemic diseases can result in systolic impairment and left ventricular dilatation, but in the majority of patients, no identifiable cause is found. At least 25% of adult patients with DCM have evidence for familial disease, and 20% of adult relatives of these probands have isolated left ventricular enlargement that can progress to DCM. Numerous genetic mutations are associated with DCM in association with skeletal, neurological, and other extracardiac abnormalities, but the genetic basis in most cases of isolated DCM remains elusive. This study shows that a proportion of patients with typical DCM harbor mutations in genes that encode proteins of the intercalated discs (the end-to-end connections between cardiomyocytes responsible for maintenance of mechanical and electric integrity). Before this study, mutations in these genes were thought to be synonymous with another disease, arrhythmogenic right ventricular cardiomyopathy, but the demonstration that arrhythmogenic right ventricular cardiomyopathy and DCM share a common molecular basis indicates that these disorders may simply be different facets of the same underlying pathological process.
Conclusions: Heart failure caused by a dilated, poorly contracting left ventricle and arrhythmogenic right ventricular cardiomyopathy have been considered distinct clinicopathologic entities. This study suggests that both clinical presentations can be caused by mutations in desmosomal protein genes. 51
SERCA2a Gene Transfer Decreases Sarcoplasmic Reticulum Calcium Leak and Reduces Ventricular Arrhythmias in a Model of Chronic Heart Failure
Summary: Systolic and diastolic function in heart failure is strongly linked to decrease of calcium ion uptake into the sarcoplasmic reticulum (SR) secondary to the loss of SR calcium ATPase 2a (SERCA2a). SERCA2a gene therapy is an encouraging new therapeutic strategy that is both positively inotropic and lusitropic, and, in contrast to other positive inotropes, it imparts these benefits in an energetically favorable manner. However, there is concern that SERCA2a upregulation might be proarrhythmic in the same way as catecholamine-related inotropes. In the present study, the authors assessed the arrhythmic effects of SERCA2a gene transfer in a rat model of chronic heart failure after myocardial infarction. In vivo telemetry studies demonstrated a reduction in spontaneous, and perhaps more importantly, catecholamine-induced ventricular arrhythmias after SERCA2a gene therapy. Programmed electric stimulation studies showed reduced susceptibility to S1-S2-induced ventricular tachycardia. Leak from the internal calcium reservoir, the SR, when measured as either spontaneous "diastolic" calcium sparks, or total SR calcium leak, was reduced after SERCA2a gene therapy. SR calcium leak is a potential origin of delayed afterdepolarizations and ventricular tachyarrhythmias, and catecholamine-induced triggered activity was reduced in failing cardiomyocytes after SERCA2a gene therapy. Both direct effects of restored SERCA2a protein levels, and the indirect effects of reverse remodeling secondary to improved cardiac function, may underpin the antiarrhythmic effects observed. SERCA2a gene therapy represents a novel class of heart failure therapy in which positive inotropic and lusitropic benefits can be achieved with a concomitant antiarrhythmic effect in this animal heart failure model.
Conclusions: SERCA2a gene therapy stabilizes SR Ca 2ϩ load, reduces ryanodine receptor phosphorylation and decreases SR Ca 2ϩ leak, and reduces cellular triggered activity in vitro and spontaneous and catecholamine-induced ventricular arrhythmias in vivo in failing hearts. SERCA2a gene therapy did not therefore predispose to arrhythmias and may represent a novel antiarrhythmic strategy in heart failure. 52
Association of Left Atrial Endothelin-1 With Atrial Rhythm, Size, and Fibrosis in Patients With Structural Heart Disease
Summary: Atrial fibrillation (AF) increases risk of stroke, morbidity, and mortality. Current treatments have significant limitations. Studies that identify pathways by which we can prevent the development or progression of AF may lead to improved treatment. AF imposes a metabolic and hemodynamic strain on the atria. At the same time, increased hemodynamic burden on the atria (as a result of hypertension, mitral regurgitation or heart failure) promotes atrial enlargement and fibrosis, a substrate for AF. Left atrial (LA) enlargement is associated with poor clinical outcomes. Endothelin-1 (ET-1), a well-known vasoconstrictor peptide with mitogenic properties, is increased in the plasma of AF patients with underlying structural heart disease. In this study, both ET-1 gene expression and processing were enhanced in the LA of AF patients, and increased content was associated with increased LA size and volume. More broadly, atrial ET-1 content is increased in conditions associated with increased LA hemodynamic burden. ET-1 levels were associated with AF persistence. Atrial ET-1 mRNA levels were correlated with the mRNA expression of fibrotic mediators (platelet-derived growth factor and connective tissue growth factor), as well as with the atrial mRNA expression of brain natriuretic peptide, a predictor of AF. These associations suggest that ET-1 may promote atrial enlargement and fibrosis and contribute to increased AF persistence. It would be of interest to determine if agents or procedures that reduce ET-1 production or block its receptors have a therapeutic benefit with respect to prevention of AF or slowing its progression.
Conclusions: Elevated atrial ET-1 content is associated with increased LA size, AF rhythm, hypertension, and heart failure. ET-1 is associated with atrial dilatation, fibrosis, and hypertrophy and probably contributes to AF persistence. Interventions that reduce atrial ET-1 expression and/or block its receptors may slow AF progression. 53
Common Variants in Cardiac Ion Channel Genes Are Associated With Sudden Cardiac Death
Summary: Sudden cardiac death (SCD) results in 250 000 -400 000 deaths in the United States annually, and the majority are unheralded, occurring as the initial manifestation of heart disease. Because there is a heritable component to SCD risk, genetic markers may aid in the identification of individuals who are at an elevated risk for arrhythmic death within the population. Because rare variants in cardiac ion channel genes have been associated with SCD in rare primary arrhythmic syndromes, it is plausible that common variants in these same genes may be associated with more common forms of SCD. To address this hypothesis, the authors assembled SCD cases from 6 National Institutes of Health-funded prospective cohorts and used a prospective nested case-control design to test for associations between common genetic variation in coding and noncoding regions in 5 cardiac ion channel genes implicated in congenital long-QT syndrome and SCD among individuals of European ancestry. A noncoding variant in KCNQ1 (Pϭ0.0002) and a noncoding variant in SCN5A (Pϭ0.0005) were significantly associated with SCD after adjustment for multiple testing. The at-risk alleles are common, with population frequencies of 67% for the T-allele at rs2283222 in KCNQ1 and 60% for the C-allele at rs11720524 in SCN5A. These findings suggest that common variants with modest effects as well as rare variants with strong effects in these genes contribute to SCD risk. Further investigation into the functional abnormalities associated with noncoding variation in these genes may lead to important insights into predisposition to lethal arrhythmias in the population.
Conclusions:
In this combined analysis of 6 prospective cohort studies, 2 common intronic variants in KCNQ1 and SCN5A were associated with SCD in individuals of European ancestry. Further study in other populations and investigation into the functional abnormalities associated with noncoding variation in these genes may lead to important insights into predisposition to lethal arrhythmias. 54 
Absence of the Inhibitory G-Protein G␣ i2 Predisposes to Ventricular Cardiac Arrhythmia
Summary: Cardiac function is modulated by the sympathetic and parasympathetic arms of the autonomic nervous system. Recognition of aberrant sympathetic signaling in disease, such as heart failure, can have therapeutic implications in which ␤-adrenergic blockers are beneficial. Experimental studies have implicated roles for inhibitory G-proteins G␣ i2 , G␣ i3 , and G␣ o in parasympathetic signal transduction. However, the parasympathetic modulation of heart function through these inhibitory G-proteins has received less attention than the sympathetic nervous system. The authors studied mice with global genetic deletion of G␣ i2 and found a significant proarrhythmic substrate. The results suggest a mechanism by which attenuation of the parasympathetic system may promote ventricular arrhythmias. Expression of this inhibitory G-protein may be a mechanism by which the parasympathetic nervous system can protect against ventricular tachyarrhythmias. Future studies are required to determine whether modulation of inhibitory G-protein expression has antiarrhythmic potential in models of disease.
Conclusions:
The absence of inhibitory G-protein signaling mediated through G␣ i2 is a substrate for ventricular arrhythmias. 56
Lack of Uniform Progression of Endocardial Scar in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy and Ventricular Tachycardia
Summary: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a complex disorder with poorly understood pathophysiology. The authors sought to examine the extent to which the RV endocardial scar area and chamber dilatation associated with ARVD/C increased progressively over time. Eleven patients with ARVD/C had RV scar area and volume measured on 2 occasions a mean of 57 months apart as part of ablation procedures for ventricular tachycardia. The authors found that although RV volume nearly universally increased over time (10 of 11 patients), the low-voltage area increased in only a small minority (2 of 11 patients). These findings have important prognostic and management implications for patients with ARVD/C. They suggest that in the absence of scar enlargement, efforts to control scar-based ventricular tachycardia with ablation should be possible. In addition, future research is needed to define ways to prevent RV dilatation.
Conclusions:
In patients with ARVD/C and ventricular tachycardia, progressive RV dilatation is the rule, and rapid progression of significant macroscopic endocardial scar occurs in only a subset of patients. These results have important management implications, suggesting that efforts to prevent RV dilatation in this population are needed and that an aggressive substrate-based ablation strategy offers the potential to provide long-term ventricular tachycardia control. 57
Autonomic Remodeling in the Left Atrium and Pulmonary Veins in Heart Failure: Creation of a Dynamic Substrate for Atrial Fibrillation
Summary: Atrial fibrillation (AF) is common in patients with heart failure. Although atrial fibrosis is a likely factor, other factors probably are important, as well. This study suggests that the autonomic nervous system also contributes significantly to the formation of AF substrate in a canine model of heart failure. The authors found that unlike the failing ventricle, where there appears to be parasympathetic withdrawal, there is an increase in parasympathetic innervation in the failing atrium, which appears to contribute to the maintenance of AF. They also show that both sympathetic and parasympathetic remodeling occur and are most pronounced in the posterior left atrium. These findings support further evaluation of ablation of autonomic ganglionated plexi to improve the success AF ablation in heart failure. The data also support exploration of the parasympathetic nervous system as a therapeutic target for prevention of AF in the failing heart.
Conclusions:
In this heart failure model, autonomic and electrophysiological remodeling occurs, involving the posterior left atrium and pulmonary veins. Despite synaptic compensation, parasympathetic hyperinnervation contributes significantly to AF maintenance. Parasympathetic and/or sympathetic signaling may be possible therapeutic targets for AF in congestive heart failure. 58
Effect of Right Ventricular Versus Biventricular Pacing on Electric Remodeling in the Normal Heart
Summary: Biventricular pacing (BIV) has been shown to have beneficial effects in a subset of patients with systolic heart failure and to prevent the deleterious effects of high-burden right ventricular (RV) pacing in patients with preserved left ventricular function. The mechanisms of these salutary effects are not fully elucidated. In this study, the authors examined the effect of BIV versus RV pacing on the normal heart in a rabbit model of epicardial pacing. After 4 weeks of pacing, the QT interval was significantly shorter in the BIV group compared with the RV or sham-operated (nonpaced) groups. Also, compared with rabbits in the RV group, rabbits in the BIV group had shorter RV effective refractory period and shorter left ventricular paced QT interval during the drive train of stimuli and close to refractoriness. Also, protein expression of the KVLQT1 was significantly increased in the BIV group compared with the RV and control groups, whereas protein expression of SCN5A and con-nexin43 was significantly decreased in the RV compared with the other study groups. Erg protein expression was significantly increased in both pacing groups compared with the controls. These findings underscore the effect of the sites of pacing on electric remodeling in the normal heart and may have implications as to the effect of BIV pacing on arrhythmia incidence and burden.
Conclusions: In this rabbit model, the authors demonstrate a direct effect of BIV but not RV pacing on shortening the native QT interval as well as the paced QT interval during burst pacing and close to the ventricular effective refractory period. These findings underscore the fact that the effect of BIV pacing is partially mediated through direct electric remodeling and may have implications as to the effect of BIV pacing on arrhythmia incidence and burden. 59
Relation Between Right Ventricular Function and Increased Right Ventricular [ 18 F]Fluorodeoxyglucose Accumulation in Patients With Heart Failure
Summary: Despite significant improvements in the management of heart failure, morbidity and mortality remain high. The comorbid association of right ventricular (RV) dysfunction with left heart failure identifies patients with a particularly poor prognosis. There has been recent clinical interest in the role of metabolic modulation in the treatment of left ventricular dysfunction. An understanding of the metabolic changes in the right ventricle may serve as a potential target for the management of RV failure. This study was designed to characterize myocardial metabolism in the right ventricle of patients with left ventricular failure. RV dysfunction was associated with an increase in RV glucose uptake. This metabolic change was correlated with the severity of RV dysfunction. Larger, prospective studies are required to define the potential clinical implications of this metabolic adaptation.
Conclusions: RV dysfunction is associated with an increase in RV fluorodeoxyglucose uptake, the magnitude of which may be correlated with severity. 60
Prevalence of Left Ventricular Regional Dysfunction in Arrhythmogenic Right Ventricular Dysplasia: A Tagged MRI Study
Summary: Arrhythmogenic right ventricular cardiomyopathy or dysplasia (ARVC/D) predominantly affects the right ventricle; however, histological and molecular involvement of the left ventricle (LV) is well documented. Global LV function is usually affected in the advanced stages and is an important determinant for the need for heart transplantation. The authors evaluated regional LV strain in ARVC/D patients without overt LV dysfunction using MRI tagging. Patients with definite ARVC/D showed worse regional LV function compared with control subjects. Regional LV function was also significantly decreased in probable ARVC/D patients compared with control subjects, although right ventricular function was comparable between the groups. Thus, we report a high prevalence of regional LV dysfunction in ARVC/D despite preserved global LV function. This is in agreement with the current literature that supports the notion that ARVC/D is a biventricular disease; however, the exact significance of this finding is unclear. It is not known whether LV dysfunction is progressive in these patients, and future long-term studies addressing the prognostic significance of minor LV regional abnormalities are needed.
Conclusions: ARVD is associated with regional LV dysfunction, which appears to parallel degree of RV dysfunction. Further large studies are needed to validate this finding and to better define implications of subclinical segmental LV dysfunction. 61 
